359 related articles for article (PubMed ID: 31185671)
1. Minimal Residual Disease Monitoring with Next-Generation Sequencing Methodologies in Hematological Malignancies.
Sánchez R; Ayala R; Martínez-López J
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31185671
[TBL] [Abstract][Full Text] [Related]
2. [Recommendations for laboratory standardization of next generation sequencing in hematological malignancies].
Xu CS; Li XQ; Liu HX; Li CB; Chen Z; Cai JP; Peng MT
Zhonghua Yi Xue Za Zhi; 2019 Nov; 99(41):3204-3208. PubMed ID: 31694113
[TBL] [Abstract][Full Text] [Related]
3. Digital PCR: A Reliable Tool for Analyzing and Monitoring Hematologic Malignancies.
Coccaro N; Tota G; Anelli L; Zagaria A; Specchia G; Albano F
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32365599
[TBL] [Abstract][Full Text] [Related]
4. Clinical molecular testing for ASXL1 c.1934dupG p.Gly646fs mutation in hematologic neoplasms in the NGS era.
Montes-Moreno S; Routbort MJ; Lohman EJ; Barkoh BA; Kanagal-Shamanna R; Bueso-Ramos CE; Singh RR; Medeiros LJ; Luthra R; Patel KP
PLoS One; 2018; 13(9):e0204218. PubMed ID: 30222780
[TBL] [Abstract][Full Text] [Related]
5. Integration of Technical, Bioinformatic, and Variant Assessment Approaches in the Validation of a Targeted Next-Generation Sequencing Panel for Myeloid Malignancies.
Thomas M; Sukhai MA; Zhang T; Dolatshahi R; Harbi D; Garg S; Misyura M; Pugh T; Stockley TL; Kamel-Reid S
Arch Pathol Lab Med; 2017 Jun; 141(6):759-775. PubMed ID: 28557600
[TBL] [Abstract][Full Text] [Related]
6. Principles of analytical validation of next-generation sequencing based mutational analysis for hematologic neoplasms in a CLIA-certified laboratory.
Kanagal-Shamanna R; Singh RR; Routbort MJ; Patel KP; Medeiros LJ; Luthra R
Expert Rev Mol Diagn; 2016; 16(4):461-72. PubMed ID: 26765348
[TBL] [Abstract][Full Text] [Related]
7. Molecular Minimal Residual Disease Testing in Acute Myeloid Leukemia: A Review for the Practicing Clinician.
Hantel A; Stock W; Kosuri S
Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):636-647. PubMed ID: 30006258
[TBL] [Abstract][Full Text] [Related]
8. Applications of next-generation sequencing in hematologic malignancies.
Ramkissoon LA; Montgomery ND
Hum Immunol; 2021 Nov; 82(11):859-870. PubMed ID: 33648805
[TBL] [Abstract][Full Text] [Related]
9. Clinical actionability of measurable residual disease (MRD) assessment in the management of patients with hematologic malignancies: a case-based monograph.
Wolf J; Fonseca R; Muffly L
Clin Adv Hematol Oncol; 2020 Mar; 18 Suppl 9(3):1-16. PubMed ID: 33843875
[TBL] [Abstract][Full Text] [Related]
10. Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?
Kotrova M; Trka J; Kneba M; Brüggemann M
Mol Diagn Ther; 2017 Oct; 21(5):481-492. PubMed ID: 28452038
[TBL] [Abstract][Full Text] [Related]
11. Next-generation sequencing for measurable residual disease detection in acute myeloid leukaemia.
Ghannam J; Dillon LW; Hourigan CS
Br J Haematol; 2020 Jan; 188(1):77-85. PubMed ID: 31804716
[TBL] [Abstract][Full Text] [Related]
12. Next-generation sequencing-based panel testing for myeloid neoplasms.
Kuo FC; Dong F
Curr Hematol Malig Rep; 2015 Jun; 10(2):104-11. PubMed ID: 25933675
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease.
Waldschmidt JM; Anand P; Knoechel B; Lohr JG
Semin Hematol; 2018 Jan; 55(1):33-37. PubMed ID: 29759150
[TBL] [Abstract][Full Text] [Related]
14. Next-Generation Sequencing Technology to Identify Minimal Residual Disease in Lymphoid Malignancies.
Kotrova M; Darzentas N; Pott C; Brüggemann M;
Methods Mol Biol; 2021; 2185():95-111. PubMed ID: 33165845
[TBL] [Abstract][Full Text] [Related]
15. Genetic alterations crossing the borders of distinct hematopoetic lineages and solid tumors: Diagnostic challenges in the era of high-throughput sequencing in hemato-oncology.
Shumilov E; Flach J; Pabst T; Fiedler M; Angelillo-Scherrer A; Trümper L; Joncourt R; Kohlmann A; Bacher U
Crit Rev Oncol Hematol; 2018 Jun; 126():64-79. PubMed ID: 29759569
[TBL] [Abstract][Full Text] [Related]
16. Next-generation sequencing - feasibility and practicality in haematology.
Kohlmann A; Grossmann V; Nadarajah N; Haferlach T
Br J Haematol; 2013 Mar; 160(6):736-53. PubMed ID: 23294427
[TBL] [Abstract][Full Text] [Related]
17. The Potential Roles and Advantages of Single Cell Sequencing in the Diagnosis and Treatment of Hematological Malignancies.
Shi M; Dong X; Huo L; Wei X; Wang F; Sun K
Adv Exp Med Biol; 2018; 1068():119-133. PubMed ID: 29943300
[TBL] [Abstract][Full Text] [Related]
18. High-throughput sequencing for noninvasive disease detection in hematologic malignancies.
Scherer F; Kurtz DM; Diehn M; Alizadeh AA
Blood; 2017 Jul; 130(4):440-452. PubMed ID: 28600337
[TBL] [Abstract][Full Text] [Related]
19. Determination of complex subclonal structures of hematological malignancies by multiplexed genotyping of blood progenitor colonies.
Nice FL; Massie CE; Klampfl T; Green AR
Exp Hematol; 2018 Jan; 57():60-64.e1. PubMed ID: 29024710
[TBL] [Abstract][Full Text] [Related]
20. Multiplex technologies for the assessment of minimal residual disease and low-level mutation detection in leukaemia: mass spectrometry versus next-generation sequencing.
Shanmuganathan N; Branford S
Br J Haematol; 2022 Jan; 196(1):19-30. PubMed ID: 34124782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
